Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study.

Mariani G, Galli G, Cavalieri S, Valagussa P, Bianchi GV, Capri G, Cresta S, Ferrari L, Damian S, Duca M, de Braud F, Moliterni A.

Breast J. 2019 Mar;25(2):237-242. doi: 10.1111/tbj.13197. Epub 2019 Feb 27.

PMID:
30810258
2.

Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies.

Cona MS, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A, Poggi MM, Raggi D, Randon G, Ratta R, Signorelli D, Vernieri C, de Braud F, Verderio P, Di Nicola M.

Cancers (Basel). 2019 Feb 14;11(2). pii: E223. doi: 10.3390/cancers11020223.

3.

Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles.

Vernieri C, Prisciandaro M, Milano M, Cona MS, Maggi C, Brambilla M, Mennitto A, Fabbroni C, Farè E, Cresta S, Celio L, Mariani G, Bianchi G, Capri G, de Braud F.

Clin Breast Cancer. 2019 Apr;19(2):e306-e318. doi: 10.1016/j.clbc.2018.12.004. Epub 2018 Dec 12.

PMID:
30635175
4.

Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?

Tessari A, Pilla L, Silvia D, Duca M, Paolini B, Carcangiu ML, Mariani L, de Braud FG, Cresta S.

Breast. 2018 Dec;42:68-73. doi: 10.1016/j.breast.2018.08.106. Epub 2018 Aug 29.

PMID:
30189381
5.

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.

Schöffski P, Cresta S, Mayer IA, Wildiers H, Damian S, Gendreau S, Rooney I, Morrissey KM, Spoerke JM, Ng VW, Singel SM, Winer E.

Breast Cancer Res. 2018 Sep 5;20(1):109. doi: 10.1186/s13058-018-1015-x.

6.

Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas.

Fiedler W, Cresta S, Schulze-Bergkamen H, De Dosso S, Weidmann J, Tessari A, Baumeister H, Danielczyk A, Dietrich B, Goletz S, Zurlo A, Salzberg M, Sessa C, Gianni L.

ESMO Open. 2018 Feb 1;3(2):e000303. doi: 10.1136/esmoopen-2017-000303. eCollection 2018.

7.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG.

Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.

8.

miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer.

D'Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C, Orlandi R, Gualeni AV, Gloghini A, Rossini A, Cresta S, Tessari A, De Braud F, Di Leva G, Tripodo C, Iorio MV.

Cancer Res. 2016 Sep 15;76(18):5562-72. doi: 10.1158/0008-5472.CAN-16-0140. Epub 2016 Jul 11.

9.

A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas.

Fiedler W, DeDosso S, Cresta S, Weidmann J, Tessari A, Salzberg M, Dietrich B, Baumeister H, Goletz S, Gianni L, Sessa C.

Eur J Cancer. 2016 Aug;63:55-63. doi: 10.1016/j.ejca.2016.05.003. Epub 2016 Jun 7.

10.

Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).

Joerger M, Hess D, Delmonte A, Gallerani E, Fasolo A, Gianni L, Cresta S, Barbieri P, Pace S, Sessa C.

Br J Clin Pharmacol. 2015 Jul;80(1):128-38. doi: 10.1111/bcp.12583. Epub 2015 Jun 3.

11.

The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.

Arcaini L, Rossi D, Lucioni M, Nicola M, Bruscaggin A, Fiaccadori V, Riboni R, Ramponi A, Ferretti VV, Cresta S, Casaluci GM, Bonfichi M, Gotti M, Merli M, Maffi A, Arra M, Varettoni M, Rattotti S, Morello L, Guerrera ML, Sciarra R, Gaidano G, Cazzola M, Paulli M.

Haematologica. 2015 Feb;100(2):246-52. doi: 10.3324/haematol.2014.116855. Epub 2014 Nov 7.

12.

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.

Sessa C, Del Conte G, Christinat A, Cresta S, Perotti A, Gallerani E, Lardelli P, Kahatt C, Alfaro V, Iglesias JL, Fernández-Teruel C, Gianni L.

Invest New Drugs. 2013 Oct;31(5):1236-43. doi: 10.1007/s10637-013-9942-y. Epub 2013 Mar 7.

PMID:
23467812
13.

MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia.

De Paoli L, Cerri M, Monti S, Rasi S, Spina V, Bruscaggin A, Greco M, Ciardullo C, Famà R, Cresta S, Maffei R, Ladetto M, Martini M, Laurenti L, Forconi F, Marasca R, Larocca LM, Bertoni F, Gaidano G, Rossi D.

Leuk Lymphoma. 2013 May;54(5):1087-90. doi: 10.3109/10428194.2012.723706. Epub 2012 Nov 12. No abstract available.

PMID:
23039309
14.

The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.

Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foà R, Dalla-Favera R, Pasqualucci L, Rabadan R, Gaidano G.

J Exp Med. 2012 Aug 27;209(9):1537-51. doi: 10.1084/jem.20120904. Epub 2012 Aug 13.

15.

The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1.

Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Cresta S, Famà R, Deambrogi C, Greco M, Fangazio M, Ciardullo C, Piranda D, Casaluci GM, Messina M, Giudice ID, Chiaretti S, Marinelli M, Guarini A, Foà R, Gaidano G.

Leuk Suppl. 2012 Aug;1(Suppl 2):S26-8. doi: 10.1038/leusup.2012.16. Epub 2012 Aug 9.

16.

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.

Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, Casali PG, Balaña C, Schöffski P, Grosso F, Lardelli P, Nieto A, Alfaro V, Demetri GD.

Eur J Cancer. 2012 Nov;48(16):3036-44. doi: 10.1016/j.ejca.2012.05.012. Epub 2012 Jun 29.

PMID:
22749255
17.

Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome.

Rossi D, Rasi S, Spina V, Fangazio M, Monti S, Greco M, Ciardullo C, Famà R, Cresta S, Bruscaggin A, Laurenti L, Martini M, Musto P, Forconi F, Marasca R, Larocca LM, Foà R, Gaidano G.

Br J Haematol. 2012 Aug;158(3):426-9. doi: 10.1111/j.1365-2141.2012.09155.x. Epub 2012 May 10. No abstract available.

PMID:
22571487
18.

Analysis of SF3B1 mutations in monoclonal B-cell lymphocytosis.

Greco M, Capello D, Bruscaggin A, Spina V, Rasi S, Monti S, Ciardullo C, Cresta S, Fangazio M, Gaidano G, Foà R, Rossi D.

Hematol Oncol. 2013 Mar;31(1):54-5. doi: 10.1002/hon.2013. Epub 2012 Mar 29. No abstract available.

PMID:
22461140
19.

Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.

Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, Chiaretti S, Del Giudice I, Fabbri G, Bruscaggin A, Spina V, Deambrogi C, Marinelli M, Famà R, Greco M, Daniele G, Forconi F, Gattei V, Bertoni F, Deaglio S, Pasqualucci L, Guarini A, Dalla-Favera R, Foà R, Gaidano G.

Blood. 2012 Mar 22;119(12):2854-62. doi: 10.1182/blood-2011-12-395673. Epub 2012 Feb 3.

20.

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, Marasca R, Laurenti L, Bruscaggin A, Cerri M, Monti S, Cresta S, Famà R, De Paoli L, Bulian P, Gattei V, Guarini A, Deaglio S, Capello D, Rabadan R, Pasqualucci L, Dalla-Favera R, Foà R, Gaidano G.

Blood. 2012 Jan 12;119(2):521-9. doi: 10.1182/blood-2011-09-379966. Epub 2011 Nov 10.

21.

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.

Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M, Fangazio M, Vaisitti T, Monti S, Chiaretti S, Guarini A, Del Giudice I, Cerri M, Cresta S, Deambrogi C, Gargiulo E, Gattei V, Forconi F, Bertoni F, Deaglio S, Rabadan R, Pasqualucci L, Foà R, Dalla-Favera R, Gaidano G.

Blood. 2011 Dec 22;118(26):6904-8. doi: 10.1182/blood-2011-08-373159. Epub 2011 Oct 28.

22.

Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma.

Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, Spina V, Bruscaggin A, Monti S, Cerri M, Cresta S, Fangazio M, Arcaini L, Lucioni M, Marasca R, Thieblemont C, Capello D, Facchetti F, Kwee I, Pileri SA, Foà R, Bertoni F, Dalla-Favera R, Pasqualucci L, Gaidano G.

Blood. 2011 Nov 3;118(18):4930-4. doi: 10.1182/blood-2011-06-359166. Epub 2011 Aug 31.

23.

Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.

Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J, Grunn A, Fangazio M, Capello D, Monti S, Cresta S, Gargiulo E, Forconi F, Guarini A, Arcaini L, Paulli M, Laurenti L, Larocca LM, Marasca R, Gattei V, Oscier D, Bertoni F, Mullighan CG, Foá R, Pasqualucci L, Rabadan R, Dalla-Favera R, Gaidano G.

J Exp Med. 2011 Jul 4;208(7):1389-401. doi: 10.1084/jem.20110921. Epub 2011 Jun 13.

24.

Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia.

Rasi S, Bruscaggin A, Rinaldi A, Cresta S, Fangazio M, De Paoli L, Monti S, Gargiulo E, Kwee I, Foà R, Bertoni F, Gaidano G, Rossi D.

Leuk Res. 2011 Oct;35(10):1419-22. doi: 10.1016/j.leukres.2011.05.024. Epub 2011 Jun 12.

PMID:
21663967
25.

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

Perotti A, Locatelli A, Sessa C, Hess D, Viganò L, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F, Gianni L.

J Clin Oncol. 2010 Oct 20;28(30):4554-61. doi: 10.1200/JCO.2009.27.5867. Epub 2010 Sep 20.

PMID:
20855840
26.

Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia.

Deambrogi C, De Paoli L, Fangazio M, Cresta S, Rasi S, Spina V, Gattei V, Gaidano G, Rossi D.

Am J Hematol. 2010 Jul;85(7):541-4. doi: 10.1002/ajh.21742. No abstract available.

27.

BCL3 translocation in CLL with typical phenotype: assessment of frequency, association with cytogenetic subgroups, and prognostic significance.

Rossi D, Deambrogi C, Monti S, Cresta S, De Paoli L, Fangazio M, Giardini I, Bernasconi P, Gaidano G.

Br J Haematol. 2010 Sep;150(6):702-4. doi: 10.1111/j.1365-2141.2010.08255.x. No abstract available.

PMID:
20553272
28.

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel.

Sessa C, Tosi D, Viganò L, Albanell J, Hess D, Maur M, Cresta S, Locatelli A, Angst R, Rojo F, Coceani N, Rivera VM, Berk L, Haluska F, Gianni L.

Ann Oncol. 2010 Jun;21(6):1315-22. doi: 10.1093/annonc/mdp504. Epub 2009 Nov 9.

PMID:
19901013
29.

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

Sessa C, Cresta S, Noberasco C, Capri G, Gallerani E, De Braud F, Zucchetti M, D'Incalci M, Locatelli A, Marsoni S, Corradino I, Minoia C, Zintl P, Gianni L.

Eur J Cancer. 2009 Aug;45(12):2116-22. doi: 10.1016/j.ejca.2009.04.002. Epub 2009 May 4.

PMID:
19419856
30.

Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours.

Perotti A, Sessa C, Mancuso A, Noberasco C, Cresta S, Locatelli A, Carcangiu ML, Passera K, Braghetti A, Scaramuzza D, Zanaboni F, Fasolo A, Capri G, Miani M, Peters WP, Gianni L.

Ann Oncol. 2009 Apr;20(4):741-5. doi: 10.1093/annonc/mdn695. Epub 2009 Feb 3.

PMID:
19190075
31.

The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.

Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S, De Paoli L, Spina V, Gattei V, Capello D, Forconi F, Lauria F, Gaidano G.

Clin Cancer Res. 2009 Feb 1;15(3):995-1004. doi: 10.1158/1078-0432.CCR-08-1630.

32.

Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.

Sessa C, Perotti A, Noberasco C, De Braud F, Gallerani E, Cresta S, Zucchetti M, Viganò L, Locatelli A, Jimeno J, Feilchenfeldt JW, D'Incalci M, Capri G, Ielmini N, Gianni L.

Eur J Cancer. 2009 May;45(7):1153-61. doi: 10.1016/j.ejca.2008.11.019. Epub 2008 Dec 27.

PMID:
19114300
33.

14q32 Translocations and risk of Richter transformation in chronic lymphocytic leukaemia.

Deambrogi C, Cresta S, Cerri M, Rasi S, De Paoli L, Ramponi A, Gaidano G, Rossi D.

Br J Haematol. 2009 Jan;144(1):131-3. doi: 10.1111/j.1365-2141.2008.07398.x. Epub 2008 Oct 16. No abstract available.

PMID:
18950454
34.

CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia.

Rossi D, Zucchetto A, Rossi FM, Capello D, Cerri M, Deambrogi C, Cresta S, Rasi S, De Paoli L, Bodoni CL, Bulian P, Del Poeta G, Ladetto M, Gattei V, Gaidano G.

Haematologica. 2008 Oct;93(10):1575-9. doi: 10.3324/haematol.13103. Epub 2008 Jul 18.

35.

Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.

Cresta S, Sessa C, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A, Bertoni F, Viganò L, Maur M, Capri G, Maccioni E, Tosi D, Gianni L.

Eur J Cancer. 2008 Sep;44(13):1829-34. doi: 10.1016/j.ejca.2008.05.022. Epub 2008 Jul 17.

PMID:
18640031
36.

Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome.

Rossi D, Cerri M, Capello D, Deambrogi C, Rossi FM, Zucchetto A, De Paoli L, Cresta S, Rasi S, Spina V, Franceschetti S, Lunghi M, Vendramin C, Bomben R, Ramponi A, Monga G, Conconi A, Magnani C, Gattei V, Gaidano G.

Br J Haematol. 2008 Jun;142(2):202-15. doi: 10.1111/j.1365-2141.2008.07166.x. Epub 2008 May 19.

PMID:
18492108
37.

5-hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms.

Velati D, Viana M, Cresta S, Mantegazza P, Testa L, Bettucci D, Rinaldi M, Sances G, Tassorelli C, Nappi G, Canonico PL, Martignoni E, Genazzani AA.

Eur J Pharmacol. 2008 Feb 2;580(1-2):43-7. Epub 2007 Oct 30.

PMID:
18035351
38.

Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule.

Sessa C, Perotti A, Lladò A, Cresta S, Capri G, Voi M, Marsoni S, Corradino I, Gianni L.

Ann Oncol. 2007 Sep;18(9):1548-53.

PMID:
17761711
39.

JAK2V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia.

Rossi D, Cresta S, Destro T, Vendramin C, Bocchetta S, De Paoli L, Cerri M, Lunghi M, Gaidano G.

Br J Haematol. 2007 Sep;138(6):813-4. Epub 2007 Jul 23. No abstract available.

PMID:
17645778
40.

Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.

Sessa C, Cresta S, Cerny T, Baselga J, Rota Caremoli E, Malossi A, Hess D, Trigo J, Zucchetti M, D'Incalci M, Zaniboni A, Capri G, Gatti B, Carminati P, Zanna C, Marsoni S, Gianni L.

Ann Oncol. 2007 Mar;18(3):561-8. Epub 2006 Dec 5.

PMID:
17150998
41.

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA.

J Clin Oncol. 2006 Mar 1;24(7):1195-203.

PMID:
16505440
42.

Anthracyclines.

Gianni L, Grasselli G, Cresta S, Locatelli A, Viganò L, Minotti G.

Cancer Chemother Biol Response Modif. 2003;21:29-40. Review. No abstract available.

PMID:
15338739
43.

A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer.

Cresta S, Grasselli G, Mansutti M, Martoni A, Lelli G, Capri G, Buzzi F, Cuna GR, Jirillo A, Terzoli E, Frevola L, Tarenzi E, Sguotti C, Azli N, Murawsky M, Gianni L.

Ann Oncol. 2004 Mar;15(3):433-9.

44.

Cardiotoxic effects of anthracycline-taxane combinations.

Perotti A, Cresta S, Grasselli G, Capri G, Minotti G, Gianni L.

Expert Opin Drug Saf. 2003 Jan;2(1):59-71. Review.

PMID:
12904125
45.

Anthracyclines.

Gianni L, Grasselli G, Cresta S, Locatelli A, Viganò L, Minotti G.

Cancer Chemother Biol Response Modif. 2002;20:59-69. Review. No abstract available.

PMID:
12703200
46.

Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer.

Grasselli G, Viganò L, Capri G, Locatelli A, Tarenzi E, Spreafico C, Bertuzzi A, Giani A, Materazzo C, Cresta S, Perotti A, Valagussa P, Gianni L.

J Clin Oncol. 2001 Apr 15;19(8):2222-31.

PMID:
11304775
47.

Chromogranin A measurement in neuroendocrine tumors.

Ferrari L, Seregni E, Martinetti A, Van Graafeiland B, Nerini-Molteni S, Botti C, Artale S, Cresta S, Bombardieri E.

Int J Biol Markers. 1998 Jan-Mar;13(1):3-9. Review.

PMID:
9681293
48.

Simple identification of dominant p53 mutants by a yeast functional assay.

Inga A, Cresta S, Monti P, Aprile A, Scott G, Abbondandolo A, Iggo R, Fronza G.

Carcinogenesis. 1997 Oct;18(10):2019-21.

PMID:
9364015

Supplemental Content

Loading ...
Support Center